TrialsgrambetaRCTs are beautiful

MENSA

2014

Mepolizumab Treatment in Severe Eosinophilic Asthma

In 576 patients with severe eosinophilic asthma, subcutaneous mepolizumab 100 mg every 4 weeks reduced exacerbations compared with placebo.

Result

Primary endpoint: Annual exacerbation rate

53% reduction (p<0.001); FEV1 +98 mL.

Original publication
Subtopic
Anti-IL-5 biologic
Design
Multicentre phase-3 RCT
Relevance
Important: one of several pillars.
Source
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.doi 10.1056/NEJMoa1403290

Discussion & critique

Defined SC mepolizumab 100 mg q4wk as the standard dose for severe eosinophilic asthma.